A personalized cancer vaccine cuts melanoma mortality by roughly 50%. An AI agent finds forgotten money. And multiplayer agents threaten Microsoft’s moat. We break it all down on The Brainstorm.
Watch.
Last week, Moderna and Merck reported positive Phase 3 results for intismeran autogene in patients with high-risk melanoma. Paired with Merck's Keytruda, Moderna’s drug was administered after the surgical removal of a patient's tumor. The combination drug became the first
